Transcript
Expert insights: CSU treatment advances
Gülseren Tuncay outlines recent advances in CSU treatment, explaining how newly approved and emerging treatments may change disease management approaches and drug selection. View transcript.
Gülseren Tuncay, MD
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speakers and is not adjusted by Medthority.
Yeah, because of these new drugs, presenting as new drugs, once these medications are included in reimbursement schemes, it's likely that omalizumab will continue to be maybe used initially, or as a second line treatment, given that newer drugs are still relatively recent.
However, as real world data emerge, dupilumab may be considered as an alternative, especially in patients with atopic diseases who do not achieve adequate control with omalizumab maybe. And remibrutinib, which has demonstrated clear efficacy, particularly in angioedema patients.
So it may become more prominent, especially wheals plus angioedema phenotype because CSU patients, most of them have this phenotype. And then moreover, the fact that remibrutinib is available, an oral tablet may improve patient adherence, making it a more attractive option in clinical practise. And for patients on high dose omalizumab, I believe that the dupilumab and remibrutinib could be more comfortable as alternative in cases where patients do not respond to a standard dose when we want to up dose omalizumab, it can be considered maybe against or switching to dupilumab or remibrutinib could help avoid additional injections and improve patient's compliance. And therefore, I expect these alternatives will become more widely used in such scenarios.
Gülseren Tuncay, MD
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently by Medthority who previously received educational funding from Novartis in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.